Industry Briefs: July 2, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Arena Pharmaceuticals and Eisai have received FDA approval for a new molecular entity, Belviq (lorcaserin hydrochloride), for treating chronic weight management.
Astellas Pharma has received approval for a new molecular entity, Myrbetriq (mirabegron) extended-release, for treating adults with overactive bladder.
Biogen Idec and Isis Pharmaceuticals have announced a global collaboration for an antisense program targeting myotonic dystrophy.
Encap Drug Delivery has invested $2 million to expand its facilities, for equipment for product mixing and capsule-filling.
GEA Pharma Systems has agreed to supply a continuous manufacturing line for solid-dose products to an undisclosed pharmaceutical company.
Janssen-Cilag, a Johnson & Johnson subsidiary, has completed the acquisition of Corimmun, a privately held German-based drug-development company.
Takeda Farmacêutica Brasil, a subsidiary of Takeda Pharmaceutical has completed its acquisition of Multilab.
People News
Alnylam Pharmaceuticals has expanded its management team. The company has appointed Oved Amitay as vice-president, head of commercial; Akshay Vaishnaw as executive vice-president and chief medical officer; Jared Gollob as vice-president of clinical research; and Lubomir Nechev as vice-president of process sciences.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.